Cargando…

Efficacy of bevacizumab and chemotherapy in the first-line treatment of metastatic colorectal cancer: broadening KRAS-focused clinical view

BACKGROUND: The aim of the present retrospective study was to analyze clinical outcome and risk factors associated with treatment outcomes according to KRAS status in patient with metastatic colorectal cancer (mCRC) treated with bevacizumab (bev) plus chemotherapy in the first-line setting. METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bencsikova, Beatrix, Bortlicek, Zbynek, Halamkova, Jana, Ostrizkova, Lenka, Kiss, Igor, Melichar, Bohuslav, Pavlik, Tomas, Dusek, Ladislav, Valik, Dalibor, Vyzula, Rostislav, Zdrazilova-Dubska, Lenka
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4376345/ https://www.ncbi.nlm.nih.gov/pubmed/25888291 http://dx.doi.org/10.1186/s12876-015-0266-6

Ejemplares similares

Bevacizumab with 5-fluorouracil, leucovorin, and oxaliplatin versus bevacizumab with capecitabine and oxaliplatin for metastatic colorectal carcinoma: results of a large registry-based cohort analysis
por: Buchler, Tomas, et al.
Publicado: (2014)

Efficacy and safety of bevacizumab in elderly patients with metastatic colorectal cancer: results from the Czech population-based registry
por: Slavicek, Lubomir, et al.
Publicado: (2014)

Circulating T cell subsets are associated with clinical outcome of anti-VEGF-based 1st-line treatment of metastatic colorectal cancer patients: a prospective study with focus on primary tumor sidedness
por: Bencsikova, Beatrix, et al.
Publicado: (2019)

Role of platelet chemokines, PF-4 and CTAP-III, in cancer biology
por: Pilatova, Katerina, et al.
Publicado: (2013)

B-Cell Activating Factor as a Cancer Biomarker and Its Implications in Cancer-Related Cachexia
por: Rihacek, Michal, et al.
Publicado: (2015)

Editorial: Precision/Personalized Pediatric Oncology and Immune Therapies: Rather Customize Than Randomize
por: Kýr, Michal, et al.
Publicado: (2020)

Utilization and efficacy of second-line targeted therapy in metastatic renal cell carcinoma: data from a national registry
por: Lakomy, Radek, et al.
Publicado: (2017)

LightCycler SeptiFast technology in patients with solid malignancies: clinical utility for rapid etiologic diagnosis of sepsis
por: Dubská, Lenka, et al.
Publicado: (2012)

Surface-enhanced laser desorption/ionization time-of-flight proteomic profiling of breast carcinomas identifies clinicopathologically relevant groups of patients similar to previously defined clusters from cDNA expression
por: Brozkova, Kristyna, et al.
Publicado: (2008)

Colorectal Tumour Mucosa Microbiome Is Enriched in Oral Pathogens and Defines Three Subtypes That Correlate with Markers of Tumour Progression
por: Zwinsová, Barbora, et al.
Publicado: (2021)

Assessment of Immune Response Following Dendritic Cell-Based Immunotherapy in Pediatric Patients With Relapsing Sarcoma
por: Fedorova, Lenka, et al.
Publicado: (2019)

Dendritic Cell-Based Immunotherapy in Advanced Sarcoma and Neuroblastoma Pediatric Patients: Anti-cancer Treatment Preceding Monocyte Harvest Impairs the Immunostimulatory and Antigen-Presenting Behavior of DCs and Manufacturing Process Outcome
por: Hlavackova, Eva, et al.
Publicado: (2019)

Adjustment of serum HE4 to reduced glomerular filtration and its use in biomarker-based prediction of deep myometrial invasion in endometrial cancer
por: Chovanec, Josef, et al.
Publicado: (2017)

PET/CT-tailored treatment of locally advanced oesophago-gastric junction adenocarcinoma: a report on the feasibility of the multicenter GastroPET study
por: Obermannova, Radka, et al.
Publicado: (2022)

Sequential therapy with bevacizumab and EGFR inhibitors for metastatic colorectal carcinoma: a national registry-based analysis
por: Buchler, Tomas, et al.
Publicado: (2018)

MicroRNAs as outcome predictors in patients with metastatic colorectal cancer treated with bevacizumab in combination with FOLFOX
por: Kiss, I., et al.
Publicado: (2017)

Molecular portraits of colorectal cancer morphological regions
por: Budinská, Eva, et al.
Publicado: (2023)

Minimal Residual Disease–Guided Intermittent Dosing in Patients With Cancer: Successful Treatment of Chemoresistant Anaplastic Large Cell Lymphoma Using Intermittent Lorlatinib Dosing
por: Pokorna, Petra, et al.
Publicado: (2022)

Estimating the number of colorectal cancer patients treated with anti-tumour therapy in 2015: the analysis of the Czech National Cancer Registry
por: Pavlík, Tomáš, et al.
Publicado: (2012)

Hidden threat of tortoise ticks: high prevalence of Crimean-Congo haemorrhagic fever virus in ticks Hyalomma aegyptium in the Middle East
por: Široký, Pavel, et al.
Publicado: (2014)

Using real-time ascertainment rate estimate from infection and hospitalization dataset for modeling the spread of infectious disease: COVID-19 case study in the Czech Republic
por: Přibylová, Lenka, et al.
Publicado: (2023)

MiR-215-5p is a tumor suppressor in colorectal cancer targeting EGFR ligand epiregulin and its transcriptional inducer HOXB9
por: Vychytilova-Faltejskova, Petra, et al.
Publicado: (2017)

Electrically conductive composite materials with incorporated waste and secondary raw materials
por: Baranek, Simon, et al.
Publicado: (2023)

1563MO CoVigi phase IV multicentric trial evaluating COVID-19 vaccination adverse events and immune response dynamics in cancer patients: First results on antibody and cellular immunity
por: Obermannova, R., et al.
Publicado: (2021)

Common polymorphisms in GSTM1, GSTT1, GSTP1, GSTA1 and susceptibility to colorectal cancer in the Central European population
por: Hezova, Renata, et al.
Publicado: (2012)

Tobacco Treatment Outcomes in Patients With and Without a History of Depression, Czech Republic, 2005–2010
por: Stepankova, Lenka, et al.
Publicado: (2013)

Dysregulation of KRAS signaling in pancreatic cancer is not associated with KRAS mutations and outcome
por: Lemstrova, Radmila, et al.
Publicado: (2017)

Comprehensive Molecular Profiling for Relapsed/Refractory Pediatric Burkitt Lymphomas—Retrospective Analysis of Three Real-Life Clinical Cases—Addressing Issues on Randomization and Customization at the Bedside
por: Polaskova, Kristyna, et al.
Publicado: (2020)

Identification and functional screening of microRNAs highly deregulated in colorectal cancer
por: Faltejskova, Petra, et al.
Publicado: (2012)

A Pathological Complete Response to the Combination of Ipilimumab and Nivolumab in a Patient with Metastatic Renal Cell Carcinoma
por: Studentova, Hana, et al.
Publicado: (2022)

Impact of Carbon Particle Character on the Cement-Based Composite Electrical Resistivity
por: Černý, Vít, et al.
Publicado: (2021)

MicroRNA expression profiling identifies miR-31-5p/3p as associated with time to progression in wild-type RAS metastatic colorectal cancer treated with cetuximab
por: Mlcochova, Jitka, et al.
Publicado: (2015)

Circulating miR-378 and miR-451 in serum are potential biomarkers for renal cell carcinoma
por: Redova, Martina, et al.
Publicado: (2012)

MicroRNA expression profile associated with response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer patients
por: Svoboda, Marek, et al.
Publicado: (2012)

miR-155 and miR-484 Are Associated with Time to Progression in Metastatic Renal Cell Carcinoma Treated with Sunitinib
por: Merhautova, Jana, et al.
Publicado: (2015)

Akt expression and compartmentalization in prediction of clinical outcome in HER2-positive metastatic breast cancer patients treated with trastuzumab
por: GRELL, PETER, et al.
Publicado: (2012)

Attenuated Total Reflection Fourier Transform Infrared Spectroscopy for Forensic Screening of Long-Term Alcohol Consumption from Human Nails
por: Mitu, Bilkis, et al.
Publicado: (2023)

Nationwide increases in anti-SARS-CoV-2 IgG antibodies between October 2020 and March 2021 in the unvaccinated Czech population
por: Piler, Pavel, et al.
Publicado: (2022)

Richer concepts are better remembered: number of features effects in free recall
por: Hargreaves, Ian S., et al.
Publicado: (2012)

Outcomes According to MSKCC Risk Score with Focus on the Intermediate-Risk Group in Metastatic Renal Cell Carcinoma Patients Treated with First-Line Sunitinib: A Retrospective Analysis of 2390 Patients
por: Fiala, Ondrej, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_15kpc14t4ku3t00tqt7dnna9c2